GSK (LON:GSK) Given “Underweight” Rating at JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by JPMorgan Chase & Co. in a note issued to investors on Friday,Digital Look reports.

Separately, Berenberg Bank cut their target price on GSK from GBX 1,820 ($23.56) to GBX 1,600 ($20.71) and set a “buy” rating on the stock in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($23.38).

GSK Stock Up 0.4 %

Shares of GSK stock opened at GBX 1,483.50 ($19.21) on Friday. The stock has a market capitalization of £60.20 billion, a price-to-earnings ratio of 23.96, a PEG ratio of 1.24 and a beta of 0.31. GSK has a twelve month low of GBX 1,282.50 ($16.60) and a twelve month high of GBX 1,823.50 ($23.61). The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The business’s 50 day simple moving average is GBX 1,453.58 and its 200-day simple moving average is GBX 1,434.04.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Wendy Becker purchased 536 shares of GSK stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average price of GBX 1,515 ($19.61) per share, for a total transaction of £8,120.40 ($10,513.21). Also, insider Emma Walmsley sold 38,459 shares of GSK stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.36), for a total transaction of £545,348.62 ($706,044.30). Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.